SpringWorks Therapeutics (SWTX) is in advanced discussions to be acquired by Merck KGaA, the German company said Thursday, with the potential deal valued at around $47 per share.
The company said the negotiations are ongoing but clarified that no definitive agreement has been signed so far.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.